首页AutophagyALK
ALK
T1661 Crizotinib Crizotinib is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.
T1726 SB 431542 SB-431542 is a potent and selective inhibitor of ALK5 (IC50: 94 nM) and is also an inhibitor of ALK4 (IC50: 140 nM) and ALK7.
T1791 LDK378 Ceritinib (LDK378) is a specific ALK inhibitor (IC50: 0.2 nM).
T1800 GW 788388 GW788388 is a potent and selective inhibitor of ALK5, also inhibits TGF-(beta) type II receptor and activin type II receptor activities.
T1900 LDN212854 LDN-212854, a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared t
T1914 K 02288 K02288 is a novel small molecule inhibitor of ALK1/2/3/6.
T1935 LDN193189 LDN193189 (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8/0.8/5.3/16.7 nM for ALK1/2/3/6).
T1936 Alectinib CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
T1942 DMH1 DMH-1 is a potent and selective BMP inhibitor.
T1943 ML347 ML347(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.
T1944 LDN214117 LDN-214117 is a potent and selective ALK2 inhibitor.
T1962 ASP 3026 ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncog
T2098 A77-01 A 77-01 is a potent inhibitor of TGF-(beta) type I receptor superfamily activin-like kinase ALK5 with IC50 of 25 nM.
T2251 TAE684 NVP-TAE 684 is a excellently effective and specific ALK inhibitor(IC50=3 nM).
T2449 D 4476 D4476 is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).
T2462 SB505124 SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5.
T2612 CEP28122 CEP-28122 is a highly potent and selective orally active ALK inhibitor.
T2641 KRCA0008 KRCA-0008 is an effective and specific ALK/Ack1 inhibitor (IC50: 12/4 nM); displays drug-like properties without hERG liability.
T2655 CEP37440 CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
T3031 ALK5 Inhibitor IV A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 with IC50 values of 12 nM, 45 nM and 7.5 n
T3041 ALK inhibitor 2 ALK inhibitor 2 is a new-type and selective inhibitor for the ALK kinase.
T3059 AP26113 AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
T3061 Lorlatinib PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineo
T3079 GSK1838705A GSK1838705A is an effective IGF-1R inhibitor (IC50: 2.0 nM), modestly potent to IR (IC50: 1.6 nM) and ALK (IC50: 0.5 nM), respectively, and little inhibition to other protein kinas
T3550 Ensartinib Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon ora
T3621 Brigatinib Brigatinib is a highly potent and selective ALK inhibitor.
T3678 Entrectinib Entrectinib is an inhibitor of TrkA (IC50: 1.7 nM), TrkB (IC50: 0.1 nM), and TrkC (IC50: 0.1 nM), as well as anaplastic lymphoma kinase (ALK; IC50: 1.6 nM) and C-ros oncogene 1 (RO
T4015 HG-14-10-04 HG-14-10-04 is a potent and specific ALK inhibitor.
T4071 TPX0005 TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
T6158 LDN-193189 HCl LDN193189 hydrochloride is a selective BMP type I receptor kinases inhibitor.
T6337 RepSox RepSox is a potent and selective of the TGFβR-1/ALK5 inhibitor.
T6496 Vactosertib Vactosertib is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like
T4257 Belizatinib Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.
T4975 SM 16 SM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
T1763 SB525334 SB-525334 is a potent and selective inhibitor of the TGF-β1R and ALK5 (IC50: 14.3 nM).
T5197 BIBF0775 BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).
T8152 6-Demethoxytangeretin 6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus depressa.
T8108 Blu-782 Blu-782 is a activin receptor-like kinase-2 (ALK2) inhibitor ( IC50 of <10 nM)
T8399 Crizotinib hydrochloride Crizotinib hydrochloride is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
T8387 Alectinib hydrochloride Alectinib hydrochloride is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)
T13781 MS4077 MS4077 is an degrader of anaplastic lymphoma kinase (ALK) PROTAC(Kd of 37 nM for binding affinity to ALK).
T10442 A 83-01 sodium salt A 83-01 sodium salt is a potent inhibitor of ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50s: 12, 45 and 7.5 nM against the transcription indu
T10287 ALK2-IN-2 ALK2-IN-2 is a potent and selective inhibitor of ALK2 (IC50: 9 nM), and over 700-fold selectivity against ALK3.
T10283 ALK-IN-5 ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK, IC50: 2.9 nM).
T10426 AZ12601011 AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor (IC50: 18 nM; Kd: 2.9 nM) with inhibitory to mammary tumor growth. AZ12601011 inhibits phosphorylation of SMAD2 vi
T15262 Vactosertib Hydrochloride Vactosertib Hydrochloride is an orally active and ATP-competitive ALK5 inhibitor (IC50: 12.9 nM). It has potently antimetastatic activity and anticancer effect. Vactosertib Hydroch
T13138 TGFBR1-IN-1 TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).
T15572 IN-1130 IN-1130 is a highly selective inhibitor of transforming growth factor-β type I receptor kinase (ALK5) (IC50: 5.3 nM for ALK5-mediated Smad3 phosphorylation). IN-1130 inhibits ALK5
T16708 R-268712 R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor.
T13352 Wy 49051 Wy 49051 is an orally active antagonist of H1 receptor(IC50 of 44 nM).
T13421 (-)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate is an agonist of muscarinic receptor.
T16239 N-Methylisatoic anhydride N-Methylisatoic anhydride is a 2'-OH selective acylation agent of RNAs. It is also widely used for resolving secondary RNA structures using the SHAPE technology.
T1791L LDK378 dihydrochloride Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50
T22324 Ensartinib dihydrochloride Ensartinib (X-396) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inh
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。